Key leadership changes for Novogen
14 March 2017 via Biotech Dispatch: Australian oncology-focused biotechnology company Novogen (ASX:NRT) has announced changes to the company’s senior management it says are designed to support the its transformation from a discovery research organisation to one focused on clinical development.
The company’s GDC-0084 is preparing for phase II and Cantrixil is now in phase I trials.
The company said in a statement it has recruited additional expertise to the team, with the appointments of Dr Gordon Hirsch as Chief Medical Officer, Dr Peng Leong as Chief Business Officer, and David Cain as Director of Chemistry, Manufacturing, and Controls (CMC).
Read more in Biotech Dispatch.